Tralokinumab: Unveiling the Potential of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a promising treatment for severe dermatitis. This specific antibody inhibits IL-13, https://www.targetmol.com/compound/tralokinumab